Penumbra Inc Stock
Price
Target price
€224.70
€224.70
1.260%
2.8
1.260%
-
09.10.25 / Frankfurt
WKN: A14Y65 / Name: Penumbra / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Penumbra Inc in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Penumbra Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Penumbra Inc | 1.260% | 2.556% | -2.895% | 28.034% | -1.100% | 20.806% | 25.531% |
| Bio-Rad Labs Inc. A | -2.730% | -0.194% | 8.453% | -17.092% | -18.306% | -36.626% | -46.542% |
| Neogen Corp. | -11.860% | 4.839% | 8.333% | -59.055% | -56.667% | - | - |
| Haemonetics Corp. | -1.400% | 1.435% | -7.018% | -36.716% | -43.841% | -44.575% | -46.329% |
News
Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP
3 Mid-Cap Medical Stocks Outperforming the Market
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and
